Origin
In late February 2021, several social media users alleged U.S. President Joe Biden used the N-word while addressing world leaders at a virtual event to discuss international security policies.
As part of the Munich Security Conference, an annual event that convenes hundreds of policy makers from across the world, Biden spoke on camera for roughly 20 minutes on Feb. 19, describing his administration’s desire to be on good terms with the European Union.
Approximately three-quarters of the way into his remarks, social media users alleged he uttered the racial slur referring to Black people. Some people accused the president of saying the N-word accidentally, while others raised the possibility that he intentionally made the alleged racist comment.
Two speech-language pathologists from the University of Nebraska-Lincolnâs Special Education and Communication Disorders department are starting a new support group for people who stutter.Â
Naomi Rodgers, assistant professor in the Department of Special Education and Communication Disorders, said that along with lecturer Jessie Kohn, she is fostering a welcoming environment for young people who stutter. This new support group is part of a local chapter of the National Stuttering Organization.Â
Rodgers already facilitates a support group for adults in Lincoln and Omaha, but she said she recognized a growing need for community support for families whose children stutter.Â
âWe wanted to start a support group because stuttering happens in only about 1% of the population and [children] who stutter may have never met another individual who can relate,â Kohn said.Â
Highlander Post Views: 1,658
UCRâs School of Medicine is partnering with Emalex Biosciences in producing a biological treatment for stuttering and will lead the second phase of clinical trials.
UCR will serve as the lead site for a Phase 2 clinical trial that will evaluate the effectiveness of ecopipam, an investigational drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients. Emalex Biosciences who developed ecopipam, will conduct the clinical trial. Ecopipam currently treats talk and speech therapy. However, if the trials continue to show success and are later submitted to the U.S. Food and Drug Administration (FDA), ecopipam could become the leading biological medication to treat stuttering with FDA approval. Furthermore, ecopipam has the possibility of also treating children with Tourette syndrome, a type of disorder which involves âinvoluntary, repetitive movements and vocalization.â
Support for stutterers citizensvoice.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citizensvoice.com Daily Mail and Mail on Sunday newspapers.